ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 465,48
-0,38%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Applied Therapeutics Inc (APLT)

  7. Applied Therapeutics Inc (APLT) Actualités

APLT

Applied Therapeutics (APLT)

Applied Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:APLT
DateHeureSourceTitreSymboleSociété
17/05/202422h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/05/202413h17Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APLTApplied Therapeutics Inc
09/05/202413h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APLTApplied Therapeutics Inc
09/05/202413h00GlobeNewswire Inc.Applied Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
07/05/202413h00GlobeNewswire Inc.Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:APLTApplied Therapeutics Inc
15/04/202413h00GlobeNewswire Inc.Applied Therapeutics Appoints Dale Hooks as Chief Commercial OfficerNASDAQ:APLTApplied Therapeutics Inc
04/04/202413h00GlobeNewswire Inc.Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024NASDAQ:APLTApplied Therapeutics Inc
28/03/202421h30GlobeNewswire Inc.Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
06/03/202413h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APLTApplied Therapeutics Inc
06/03/202413h00GlobeNewswire Inc.Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
05/03/202423h42Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:APLTApplied Therapeutics Inc
28/02/202414h05GlobeNewswire Inc.Applied Therapeutics Announces $100 Million Private PlacementNASDAQ:APLTApplied Therapeutics Inc
28/02/202414h00GlobeNewswire Inc.Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
22/02/202420h26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:APLTApplied Therapeutics Inc
15/02/202413h00GlobeNewswire Inc.Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) DeficiencyNASDAQ:APLTApplied Therapeutics Inc
13/02/202422h34Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:APLTApplied Therapeutics Inc
04/01/202422h05GlobeNewswire Inc.Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic CardiomyopathyNASDAQ:APLTApplied Therapeutics Inc
03/01/202417h20Dow Jones NewsApplied Therapeutics Shares Hit 52-Week High on Govorestat FilingsNASDAQ:APLTApplied Therapeutics Inc
03/01/202413h00GlobeNewswire Inc.Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic GalactosemiaNASDAQ:APLTApplied Therapeutics Inc
23/12/202302h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APLTApplied Therapeutics Inc
09/11/202313h30GlobeNewswire Inc.Applied Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
02/11/202312h00GlobeNewswire Inc.Applied Therapeutics to Present at the UBS Biopharma Conference 2023NASDAQ:APLTApplied Therapeutics Inc
01/11/202312h00GlobeNewswire Inc.Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7NASDAQ:APLTApplied Therapeutics Inc
28/09/202313h00GlobeNewswire Inc.Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual MeetingNASDAQ:APLTApplied Therapeutics Inc
06/09/202317h08Dow Jones NewsApplied Therapeutics Shares Rise 11% After Pre-NDA Meeting With FDANASDAQ:APLTApplied Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit NDA for Govorestat (AT-007) for Treatment of Classic Galactosemia to FDA in Q4 2023NASDAQ:APLTApplied Therapeutics Inc
11/08/202322h47Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:APLTApplied Therapeutics Inc
10/08/202313h00GlobeNewswire Inc.Applied Therapeutics Reports Second Quarter 2023 Financial ResultsNASDAQ:APLTApplied Therapeutics Inc
25/07/202313h00GlobeNewswire Inc.Applied Therapeutics Provides Regulatory Update on Galactosemia ProgramNASDAQ:APLTApplied Therapeutics Inc
23/06/202322h41Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:APLTApplied Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APLT

Dernières Valeurs Consultées

LSE
IAEA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés